The cost of bureaucracy: cannabis companies lose their relative advantage

Tens of millions of dollars assigned for investment in Israel are waiting for the long-awaited approval from the regulator to allow the export of medical cannabis, but the state of Israel  has not yet structured the regulation. Meanwhile, other countries are catching up and threatening the relative advantage of the Israeli market.

Adv. Yoav Etzyon, a partner in the high-tech department, was interviewed by Globes on the subject.

For the full article, click here.